Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam

Epilepsy Research
D G Kasteleijn-Nolst TrenitéJ Oosting

Abstract

The experimental antiepileptic drug, levetiracetam (UCB L059), a piracetam analogue has been investigated in photosensitive patients in the "photosensitivity model", an early phase II study. A total of 12 patients (10 females, 2 males) with a mean age of 21.5 years (range 13-38) were investigated during a 3 day period in 3 centres (France, The Netherlands, Germany), using the same standardised method. The subjects were either treated with a single oral dose of 250 mg, 500 mg, 750 mg or 1,000 mg. In addition, 4 patients took 250 mg b.i.d. for 3-5 days, after which they were re-examined. In 9 of 12 photosensitive patients (75%) a clear suppression (3 patients) or abolishment (6 patients) of IPS evoked photoparoxysmal EEG responses was found. This effect appeared to be dose-dependent, the higher the dose the greater the effect; complete abolishment was only seen at dosages of 750 mg and 1,000 mg, occurring at peak plasma levels and lasting between 6 and 30 h. There was no indication of pharmacokinetic interaction with concomitant antiepileptic drugs such as valproic acid, ethosuximide or phenobarbitone. No serious side-effects were seen and some patients reported enhancement of their mood. Two patients with myoclonic jerks noticed...Continue Reading

References

Jan 1, 1986·Electroencephalography and Clinical Neurophysiology·C D BinnieR De Korte
May 1, 1986·Epilepsia·C D BinnieA van Wieringen
Jan 1, 1993·The Clinical Investigator·A MordenteG P Littarru
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·P BrownC D Marsden

❮ Previous
Next ❯

Citations

Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Aman BadhwarFrederick Andermann
Mar 20, 2002·Current Neurology and Neuroscience Reports·D R NordliK D Holland
Nov 30, 2000·Current Treatment Options in Neurology·K Murphy, N Delanty
Apr 16, 2011·Current Treatment Options in Neurology·Laura Mantoan, Matthew Walker
Jul 27, 2001·Neurologic Clinics·S C Schachater
Jul 20, 2001·Epilepsy Research·D Schmidt
Nov 25, 2003·Seizure : the Journal of the British Epilepsy Association·Gregory L KraussAkemi Miller
Dec 4, 2002·Epilepsia·Ali GorjiErwin-Joseph Speckmann
Oct 26, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A VerrottiF Chiarelli
Sep 9, 2005·Epilepsia·Robert S FisherUNKNOWN Epilepsy Foundation of America Working Group
Feb 13, 2008·Epilepsia·Nicola SpecchioLuigi Maria Specchio
Feb 6, 2008·Epilepsia·Pasquale StrianoSalvatore Striano
Aug 26, 2009·Epilepsia·Patricia E Penovich, L James Willmore
Nov 21, 2001·Pharmacotherapy·C A Hovinga
Aug 30, 2008·Neuropsychiatric Disease and Treatment·Antonio GambardellaAldo Quattrone
Oct 3, 2008·Neuropsychiatric Disease and Treatment·Bassel Abou-Khalil
Aug 11, 2004·Clinical Pharmacokinetics·Philip N Patsalos
Apr 17, 2003·CNS Drugs·Charles L P DeckersY A Hekster
Dec 14, 2001·Lancet·S Shorvon
Dec 19, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jacqueline A FrenchEmilia Bagiella
May 19, 2001·Neurologic Clinics·K D Holland
Apr 22, 2014·Seizure : the Journal of the British Epilepsy Association·Eunice S M Yuen, John R Sims
Nov 17, 2009·Epilepsy Research·Nicola SpecchioFederico Vigevano
Apr 24, 2007·Epilepsy Research·Dorothée G A Kasteleijn-Nolst TrenitéRenzo Guerrini
Jan 5, 2008·Developmental Medicine and Child Neurology·Alberto VerrottiPaolo Curatolo
May 23, 2013·Epilepsia·Dorotheé G A Kasteleijn-Nolst TrenitéGreg C Rigdon
Jul 4, 2006·Epilepsy Research·Dorothée G A Kasteleijn-Nolst Trenité
Dec 15, 2012·Expert Review of Neurotherapeutics·Pasquale Striano, Vincenzo Belcastro
Dec 27, 2005·Epilepsy Research·Bernd Schmidt
Feb 25, 2014·Epilepsy Research·Nicholas A Di ProsperoDorothée Kasteleijn-Nolst Trenité

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.